Chemomab Therapeutics Ltd.
| NASDAQ: CMMB | Healthcare / Biotechnology / - |
| 0.9200 | -0.1300 | -12.38% | Vol 39.24K | 1Y Perf -60.82% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 0.9100 | ASK | 0.9600 | ||
| Open | 1.03 | Previous Close | 1.05 | ||
| Pre-Market | - | After-Market | 0.95 | ||
| - - | 0.03 3.26% |
| Target Price | 16.33 | Analyst Rating | Hold 3.00 | |
| Potential % | 1.68K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | -1.84 | Earnings Rating | — | |
| Market Cap | 10.17M | Earnings Date | 10th Nov 2023 | |
| Alpha | -0.06 | Standard Deviation | 0.23 | |
| Beta | 0.32 |
Today's Price Range 0.90011.04 | 52W Range 0.99995.35 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -15.60% | ||
| 1 Month | -14.81% | ||
| 3 Months | -8.00% | ||
| 6 Months | -41.77% | ||
| 1 Year | -60.82% | ||
| 3 Years | -94.31% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -214.14 | |||
ROE last 12 Months | -48.76 | |||
ROA (5Y Avg) | -36.05 | |||
ROA last 12 Months | -45.48 | |||
ROC (5Y Avg) | -311.29 | |||
ROC last 12 Months | -44.09 | |||
Return on invested Capital Q | -16.66 | |||
Return on invested Capital Y | -20.19 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.10 | ||||
| 0.58 | ||||
| - | ||||
| - | ||||
| -1.80 | ||||
| -1.51 | ||||
| 0.58 | ||||
| 3.87 | ||||
| -20 174 100.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 8.90 | ||||
| 8.90 | ||||
| 0.00 | ||||
| 0.01 | ||||
| -1 696.60 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.80 | -0.72 | 10.00 |
| Q01 2023 | -0.80 | -0.80 | 0.00 |
| Q04 2022 | -0.80 | -0.72 | 10.00 |
| Q03 2022 | -0.60 | -0.70 | -16.67 |
| Q02 2022 | -0.60 | -0.54 | 10.00 |
| Q01 2022 | -0.40 | -0.44 | -10.00 |
| Q04 2021 | -0.40 | -0.44 | -10.00 |
| Q03 2021 | -0.02 | -0.26 | -1 200.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 10th Nov 2023 |
| Estimated EPS Next Report | -0.40 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 39.24K |
| Shares Outstanding | 11.05K |
| Shares Float | 5.87M |
| Trades Count | 177 |
| Dollar Volume | 37.68K |
| Avg. Volume | 31.95K |
| Avg. Weekly Volume | 12.49K |
| Avg. Monthly Volume | 14.88K |
| Avg. Quarterly Volume | 68.49K |
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) stock closed at 0.92 per share at the end of the most recent trading day (a -12.38% change compared to the prior day closing price) with a volume of 39.24K shares and market capitalization of 10.17M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Chemomab Therapeutics Ltd. CEO is Dale R. Pfost.
The one-year performance of Chemomab Therapeutics Ltd. stock is -60.82%, while year-to-date (YTD) performance is -71.25%. CMMB stock has a five-year performance of %. Its 52-week range is between 0.9999 and 5.35, which gives CMMB stock a 52-week price range ratio of -1.84%
Chemomab Therapeutics Ltd. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.58, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -45.48%, a ROC of -44.09% and a ROE of -48.76%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Chemomab Therapeutics Ltd., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.40 for the next earnings report. Chemomab Therapeutics Ltd.’s next earnings report date is 10th Nov 2023.
The consensus rating of Wall Street analysts for Chemomab Therapeutics Ltd. is Hold (3), with a target price of $16.33, which is +1 675.00% compared to the current price. The earnings rating for Chemomab Therapeutics Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Chemomab Therapeutics Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Chemomab Therapeutics Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.40, ATR14 : 0.07, CCI20 : -252.77, Chaikin Money Flow : 0.12, MACD : -0.04, Money Flow Index : 35.25, ROC : -14.81, RSI : 31.12, STOCH (14,3) : 7.11, STOCH RSI : 0.00, UO : 38.31, Williams %R : -92.89), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Chemomab Therapeutics Ltd. in the last 12-months were: George Adi Mor (Sold 13 800 shares of value $69 414 )
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
CEO: Dale R. Pfost
Telephone: +972 773310156
Address: Kiryat Atidim, Tel Aviv 6158002, , IL
Number of employees: 0
